{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T16:15:49Z","timestamp":1772727349580,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina de Familia. SEMERGEN"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.semerg.2025.102680","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T13:28:07Z","timestamp":1768829287000},"page":"102680","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of polypills on cardiovascular outcomes: Meta-analysis of clinical trials and observational studies"],"prefix":"10.1016","volume":"52","author":[{"given":"A.","family":"Rodr\u00edguez-Armesto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.S.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Cinza-Sanjurjo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semerg.2025.102680_bib0215","series-title":"Causas de mortalidad en Espa\u00f1a 2023","year":"2024"},{"key":"10.1016\/j.semerg.2025.102680_bib0220","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.semerg.2025.102680_bib0225","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1136\/bmj.326.7404.1419","article-title":"A strategy to reduce cardiovascular disease by more than 80%","volume":"326","author":"Wald","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.semerg.2025.102680_bib0230","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(09)60611-5","article-title":"Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial","volume":"373","author":"Indian","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.semerg.2025.102680_bib0235","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1056\/NEJMoa2028220","article-title":"Polypill with or without aspirin in persons without cardiovascular disease","volume":"384","author":"Yusuf","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semerg.2025.102680_bib0240","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.arcmed.2019.04.001","article-title":"Clinical effectiveness of the cardiovascular polypill in a real-life setting in patients with cardiovascular risk: the SORS study","volume":"50","author":"Castellano","year":"2019","journal-title":"Arch Med Res"},{"key":"10.1016\/j.semerg.2025.102680_bib0245","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1056\/NEJMoa2208275","article-title":"Polypill strategy in secondary cardiovascular prevention","volume":"387","author":"Castellano","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semerg.2025.102680_bib0250","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.recesp.2019.11.021","article-title":"Pharmacodynamic study of the cardiovascular polypill Is there any interaction among the monocomponents?","volume":"74","author":"Gonz\u00e1lez-Juanatey","year":"2021","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.semerg.2025.102680_bib0255","series-title":"WHO model list of essential medicines \u2013 23rd list, 2023 [Internet].","year":"2023"},{"key":"10.1016\/j.semerg.2025.102680_bib0260","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ahj.2013.09.014","article-title":"Untangling the relationship between medication adherence and post-myocardial infarction outcomes: medication adherence and clinical outcomes","volume":"167","author":"Choudhry","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.semerg.2025.102680_bib0265","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/01.mlr.0000163641.86870.af","article-title":"Impact of medication adherence on hospitalization risk and healthcare cost","volume":"43","author":"Sokol","year":"2005","journal-title":"Med Care"},{"key":"10.1016\/j.semerg.2025.102680_bib0270","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijcard.2022.04.085","article-title":"Polypill for cardiovascular disease prevention: systematic review and meta-analysis of randomized controlled trials","volume":"360","author":"Mohamed","year":"2022","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.semerg.2025.102680_bib0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2023.101735","article-title":"Polypill therapy in cardiovascular disease: a meta-analysis of randomized controlled trials","volume":"48","author":"Hennawi","year":"2023","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.semerg.2025.102680_bib0280","unstructured":"The BMJ. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews [Internet]. Available from: https:\/\/www.bmj.com\/content\/372\/bmj.n71. [Accessed 7 May 2025]."},{"key":"10.1016\/j.semerg.2025.102680_bib0285","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.semerg.2021.12.006","article-title":"Revisiones sistem\u00e1ticas en cinco pasos: II C\u00f3mo identificar los estudios relevantes","volume":"48","author":"Khan","year":"2022","journal-title":"Med Fam SEMERGEN"},{"key":"10.1016\/j.semerg.2025.102680_bib0290","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph20126138","article-title":"Assessing the integrity of clinical trials included in evidence syntheses","volume":"20","author":"N\u00fa\u00f1ez-N\u00fa\u00f1ez","year":"2023","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.semerg.2025.102680_bib0295","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.semerg.2025.102680_bib0300","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.semerg.2025.102680_bib0305","article-title":"Revisiones sistem\u00e1ticas en cinco pasos: III C\u00f3mo evaluar la calidad de los estudios","volume":"48","author":"Khan","year":"2022","journal-title":"Med Fam SEMERGEN"},{"key":"10.1016\/j.semerg.2025.102680_bib0310","article-title":"Revisiones sistem\u00e1ticas en cinco pasos: IV C\u00f3mo sintetizar los resultados","volume":"48","author":"Saeed Khan","year":"2022","journal-title":"Med Fam SEMERGEN"},{"key":"10.1016\/j.semerg.2025.102680_bib0315","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ijcard.2022.05.015","article-title":"The CNIC-Polypill reduces recurrent major cardiovascular events in real-life secondary prevention patients in Spain: the NEPTUNO study","volume":"361","author":"Gonz\u00e1lez-Juanatey","year":"2022","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.semerg.2025.102680_bib0320","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1177\/2047487312463278","article-title":"Use of a multidrug pill in reducing cardiovascular events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe","volume":"21","author":"Thom","year":"2014","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.semerg.2025.102680_bib0325","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/j.jacc.2014.08.021","article-title":"A polypill strategy to improve adherence: results from the FOCUS project","volume":"64","author":"Castellano","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.semerg.2025.102680_bib0330","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0140-6736(19)31791-X","article-title":"Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial","volume":"394","author":"Roshandel","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.semerg.2025.102680_bib0335","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1745-6215-12-3","article-title":"A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization","volume":"12","author":"Soliman","year":"2011","journal-title":"Trials"},{"key":"10.1016\/j.semerg.2025.102680_bib0340","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g3318","article-title":"Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care","volume":"348","author":"Selak","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.semerg.2025.102680_bib0345","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1177\/2047487314530382","article-title":"A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk","volume":"22","author":"Patel","year":"2015","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.semerg.2025.102680_bib0350","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1159\/000511064","article-title":"Use of the cardiovascular polypill in secondary prevention of cerebrovascular disease: a real-life tertiary hospital cohort study of 104 patients","volume":"10","author":"Ros-Castell\u00f3","year":"2020","journal-title":"Cerebrovasc Dis Extra"},{"key":"10.1016\/j.semerg.2025.102680_bib0355","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1186\/s12872-022-03013-w","article-title":"Safety and efficacy of a cardiovascular polypill in people at high and very high risk without a previous cardiovascular event: the international VULCANO randomised clinical trial","volume":"22","author":"Mostaza","year":"2022","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.semerg.2025.102680_bib0360","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/j.1742-1241.2010.02412.x","article-title":"A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy (\u2018polypill\u2019) on cardiovascular risk factors","volume":"64","author":"Malekzadeh","year":"2010","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.semerg.2025.102680_bib0365","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.amepre.2022.03.027","article-title":"Fixed-dose combination (polypill) for cardiovascular disease prevention: a meta-analysis","volume":"63","author":"Abushouk","year":"2022","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.semerg.2025.102680_bib0370","first-page":"e47032","article-title":"The effectiveness of polypill for the prevention of cardiovascular disease: a meta-analysis of randomized controlled trials","volume":"15","author":"Virk","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.semerg.2025.102680_bib0375","series-title":"Integrity of randomized clinical trials: how to prevent research misconduct and ensure transparency","author":"Khan","year":"2024"},{"key":"10.1016\/j.semerg.2025.102680_bib0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.semerg.2022.101877","article-title":"Evidence-based medicine needs patient and public involvement to remain relevant: a proposal for a new curriculum","volume":"49","author":"Moss","year":"2023","journal-title":"Semergen"},{"key":"10.1016\/j.semerg.2025.102680_bib0385","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.semerg.2020.06.027","article-title":"Factores asociados al riesgo cardiovascular y enfermedad cardiovascular y renal en el estudio IBERICAN (Identificaci\u00f3n de la poBlaci\u00f3n Espa\u00f1ola de RIesgo CArdiovascular y reNal): resultados definitivos","volume":"46","author":"Cinza-Sanjurjo","year":"2020","journal-title":"Med Fam SEMERGEN"},{"key":"10.1016\/j.semerg.2025.102680_bib0390","article-title":"Cost-effectiveness of a cardiovascular polypill strategy (aspirin, atorvastatin, ramipril) for the secondary prevention of cardiovascular disease based on real life improvement in risk factor control","volume":"28","author":"Rubio","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.semerg.2025.102680_bib0395","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.rce.2023.05.001","article-title":"Cost-effectiveness of the CNIC-Polypill versus separate monocomponents in cardiovascular secondary prevention in Spain","volume":"223","author":"Gonz\u00e1lez-Dom\u00ednguez","year":"2023","journal-title":"Rev Clin Esp"},{"key":"10.1016\/j.semerg.2025.102680_bib0400","doi-asserted-by":"crossref","first-page":"e007111","DOI":"10.1136\/bmjopen-2014-007111","article-title":"Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK","volume":"5","author":"Becerra","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.semerg.2025.102680_bib0405","doi-asserted-by":"crossref","first-page":"e0271908","DOI":"10.1371\/journal.pone.0271908","article-title":"Cost-effectiveness of fixed-dose combination pill (Polypill) in primary secondary prevention of cardiovascular disease: a systematic literature review","volume":"17","author":"Jahangiri","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.semerg.2025.102680_bib0410","doi-asserted-by":"crossref","first-page":"882-887.e1","DOI":"10.1016\/j.amjmed.2011.12.013","article-title":"Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients","volume":"125","author":"Naderi","year":"2012","journal-title":"Am J Med"}],"container-title":["Medicina de Familia. SEMERGEN"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1138359325002333?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1138359325002333?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T15:15:22Z","timestamp":1772723722000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1138359325002333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1138359325002333"],"URL":"https:\/\/doi.org\/10.1016\/j.semerg.2025.102680","relation":{},"ISSN":["1138-3593"],"issn-type":[{"value":"1138-3593","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of polypills on cardiovascular outcomes: Meta-analysis of clinical trials and observational studies","name":"articletitle","label":"Article Title"},{"value":"Medicina de Familia. SEMERGEN","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semerg.2025.102680","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Sociedad Espa\u00f1ola de M\u00e9dicos de Atenci\u00f3n Primaria (SEMERGEN). Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102680"}}